US12479854B2ActiveUtilityA1
Spiropyrrolidine derived antiviral agents
Est. expiryJul 29, 2041(~15.1 yrs left)· nominal 20-yr term from priority
Inventors:Ruichao ShenYong HeXuechao XingMatthew C. RhodesJoseph PanareseSamuel BartlettWei LiHui CaoJiajun ZhangXiaowen PengGuoqiang WangYat Sun Or
A61P 11/00A61K 9/0073A61K 9/0019A61P 31/14C07D 487/10
58
PatentIndex Score
0
Cited by
219
References
22
Claims
Abstract
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed:
1 . A compound represented by Formula (I), or a pharmaceutically acceptable salt thereof,
wherein:
R 1 , R 2 , R 3 , R 21 , R 22 , and R 23 are each independently selected from:
1) Hydrogen;
2) Optionally substituted —C 1 -C 8 alkyl;
3) Optionally substituted —C 2 -C 8 alkenyl;
4) Optionally substituted —C 2 -C 8 alkynyl;
5) Optionally substituted —C 3 -C 8 cycloalkyl;
6) Optionally substituted 3- to 8-membered heterocycloalkyl;
7) Optionally substituted aryl;
8) Optionally substituted arylalkyl;
9) Optionally substituted heteroaryl; and
10) Optionally substituted heteroarylalkyl;
alternatively, R 1 and R 2 are taken together with the carbon atom to which they are attached to form an optionally substituted 3- to 8-membered carbocyclic ring or an optionally substituted 3- to 8-membered heterocyclic ring;
alternatively, R 1 and R 3 are taken together with the atoms to which they are attached to form an optionally substituted 3- to 8-membered heterocyclic ring;
alternatively, R 21 and R 3 are taken together with the intervening atoms to form an optionally substituted 4- to 8-membered heterocyclic ring;
alternatively, R 22 is absent and R 21 and R 3 are taken together with the intervening atoms to form an optionally substituted 4- to 8-membered partially unsaturated heterocyclic ring or an optionally substituted 5- to 6-membered heteroaryl ring;
alternatively, R 21 and R 22 are taken together with the carbon atom to which they are attached to form an optionally substituted 3- to 8-membered carbocyclic ring or an optionally substituted 3- to 8-membered heterocyclic ring;
R 24 is selected from:
1) —C(O)R 25 ;
2) —C(O)OR 25 ;
3) —C(O)NR 13 R 14 ;
4) —S(O) 2 R 25 ;
5) Hydrogen;
6) Optionally substituted —C 1 -C 8 alkyl;
7) Optionally substituted —C 2 -C 8 alkenyl;
8) Optionally substituted —C 2 -C 8 alkynyl;
9) Optionally substituted —C 3 -C 12 cycloalkyl;
10) Optionally substituted 3- to 12-membered heterocycloalkyl;
11) Optionally substituted aryl;
12) Optionally substituted arylalkyl;
13) Optionally substituted heteroaryl;
14) Optionally substituted heteroarylalkyl;
15) —(CO)(CO)NR 13 R 14 ;
16) —(CO)(CO)R 25 ;
17) —S(O) 2 NR 13 R 14 ;
18) —C(S)R 25 ; and
19) —C(S)NR 13 R 14 ;
alternatively, R 23 and R 24 are taken together with the nitrogen atom to which they are attached to form an optionally substituted 3- to 12-membered heterocyclic ring, or an optionally substituted 5- to 12-membered heteroaryl ring;
R 25 is selected from:
1) Optionally substituted —C 1 -C 8 alkyl;
2) Optionally substituted —C 2 -C 8 alkenyl;
3) Optionally substituted —C 2 -C 8 alkynyl;
4) Optionally substituted —C 3 -C 12 cycloalkyl;
5) Optionally substituted 3- to 12-membered heterocycloalkyl;
6) Optionally substituted aryl;
7) Optionally substituted arylalkyl;
8) Optionally substituted heteroaryl; and
9) Optionally substituted heteroarylalkyl;
R 4 is hydrogen, optionally substituted —C 1 -C 4 alkyl, optionally substituted —C 2 -C 4 alkenyl, optionally substituted —C 3 -C 6 cycloalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, halogen, —CN, —OH, or a prodrug moiety;
B is an optionally substituted aryl or optionally substituted heteroaryl;
alternatively, one of R 21 and R 24 is L-, wherein L is a saturated or unsaturated linker of 4 to 20 atoms in length which is attached to B
X is selected from:
1) —CN;
2) —C(O)R 15 ;
3) —CH(OH)SO 3 R 16 ;
4) —C(O)NR 13 R 14 ,
5) —C(O)C(O)NR 13 R 14 ,
6) —CH═CH—C(O)OR 25 ,
7) —CH═CH—C(O)NR 13 R 14 ,
8) —CH═CH—S(O) 2 NR 13 R 14 ,
9) —B(OR 13 ) 2 ;
10) —C≡CR 13 ;
11) —C≡C—C(O)OR 25 ;
12) —C≡C—C(O)NR 13 R 14 ,
13) —C≡C—S(O) 2 NR 13 R 14 ;
14) —(CR 13 R 14 ) w —CN; and
15) —(CR 13 R 14 ) w —(C═O)—R 25 ;
w is 1, 2, 3, 4, or 5;
R 13 and R 14 are each independently selected from:
1) Hydrogen;
2) Optionally substituted —C 1 -C 8 alkyl;
3) Optionally substituted —C 2 -C 8 alkenyl;
4) Optionally substituted —C 2 -C 8 alkynyl;
5) Optionally substituted —C 3 -C 8 cycloalkyl;
6) Optionally substituted 3- to 8-membered heterocycloalkyl;
7) Optionally substituted aryl;
8) Optionally substituted arylalkyl;
9) Optionally substituted heteroaryl; and
10) Optionally substituted heteroarylalkyl;
alternatively, R 13 and R 14 are taken together with the nitrogen atom to which they are attached to form an optionally substituted 3- to 8-membered heterocyclic ring;
R 15 is hydrogen, hydroxy, optionally substituted —C 1 -C 8 alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl or heteroarylalkyl; and
R 16 is hydrogen or Na + .
2 . The compound of claim 1 , represented by one of Formulae (IV-1)˜(IV-4), or a pharmaceutically acceptable salt thereof:
wherein B, X, R 1 , R 3 , R 13 , R 14 , R 21 , and R 25 are as defined in claim 1 .
3 . The compound of claim 1 , represented by one of Formula (V), or a pharmaceutically acceptable salt thereof:
wherein each R 9 is independently selected from:
1) Halogen;
2) —CN;
3) —OR 13 ;
4) —SR 13 ;
5) —NR 13 R 14 ;
6) —OC(O)NR 13 R 14 ;
7) Optionally substituted —C 1 -C 6 alkyl;
8) Optionally substituted —C 3 -C 8 cycloalkyl;
9) Optionally substituted 3- to 8-membered heterocycloalkyl;
10) Optionally substituted aryl;
11) Optionally substituted heteroaryl;
12) —OC(O)R 25 ;
13) —C(O)NR 13 R 14 ;
14) —S(O)R 25 ;
15) —S(O) 2 —R 25 ;
16) —S(O)(NH)R 25 ;
17) —S(O) 2 —NR 13 R 14 ;
18) —NR 13 (C═O)R 25 ;
19) —NR 13 (C═O)OR 25 ;
20) —NR 13 (C═O)NR 13 R 14 ;
21) —NR 13 —S(O) 2 -R 25 ; and
22) —NR 13 —S(O) 2 —NR 13 R 14 ;
n is 0, 1, 2, 3, or 4; and R 1 , R 2 , R 3 , R 4 , R 13 , R 14 , R 21 , R 22 , R 23 , R 24 , R 25 and X are as defined in claim 1 .
4 . The compound of claim 1 , represented by Formula (XIX), or a pharmaceutically acceptable salt thereof:
wherein each R 9 is independently selected from:
1) Halogen;
2) —CN;
3) —OR 13 ;
4) —SR 13 ;
5) —NR 13 R 14 ;
6) —OC(O)NR 13 R 14 ;
7) Optionally substituted —C 1 -C 6 alkyl;
8) Optionally substituted —C 3 -C 8 cycloalkyl;
9) Optionally substituted 3- to 8-membered heterocycloalkyl;
10) Optionally substituted aryl;
11) Optionally substituted heteroaryl;
12) —OC(O)R 25 ;
13) —C(O)NR 13 R 14 ;
14) —S(O)R 25 ;
15) —S(O) 2 —R 25 ;
16) —S(O)(NH)R 25 ;
17) —S(O) 2 —NR 13 R 14 ;
18) —NR 13 (C═O)R 25 ;
19) —NR 13 (C═O)OR 25 ;
20) —NR 13 (C═O)NR 13 R 14 ;
21) —NR 13 —S(O) 2 R 25 ; and
22) —NR 13 —S(O) 2 NR 13 R 14 ;
n is 0, 1, 2, 3, or 4; and R 1 , R 3 , R 4 , R 21 , R 22 , R 23 , and R 24 are as defined in claim 1 .
5 . The compound of claim 1 , represented by one of Formula (VII-1)˜(VII-5), or a pharmaceutically acceptable salt thereof:
wherein R 1 , R 3 , R 21 , R 23 , R 25 , R 13 , and R 14 are as defined in claim 1 .
6 . The compound of claim 1 , represented by one of Formula (XI-1)˜(XI-3), or a pharmaceutically acceptable salt thereof:
wherein A1 is an optionally substituted 4- to 8-membered lactam or optionally substituted 2-pyridone; A2 is an optionally substituted 3- to 12-membered heterocyclic ring, or an optionally substituted 5- to 12-membered heteroaryl ring; A3 is 3- to 8-membered heterocyclic ring; R 1 , R 3 , R 21 , R 23 , and R 24 are as defined in claim 1 .
7 . The compound of claim 1 , represented by one of Formula (XVII-1)˜(XVII-2),
wherein each R 9 is independently selected from:
1) Halogen;
2) —CN;
3) —OR 13 ;
4) —SR 13 ;
5) —NR 13 R 14 ;
6) —OC(O)NR 13 R 14 ;
7) Optionally substituted —C 1 -C 6 alkyl;
8) Optionally substituted —C 3 -C 8 cycloalkyl;
9) Optionally substituted 3- to 8-membered heterocycloalkyl;
10) Optionally substituted aryl;
11) Optionally substituted heteroaryl;
12) —OC(O)R 25 ;
13) —C(O)NR 13 R 14 ,
14) —S(O)R 25 ;
15) —S(O) 2 —R 25 ;
16) —S(O)(NH)R 25 ;
17) —S(O) 2 —NR 13 R 14 ,
18) —NR 13 (C═O)R 25 ;
19) —NR 13 (C═O)OR 25 ;
20) —NR 13 (C═O)NR 13 R 14 ;
21) —NR 13 —S(O) 2 R 25 ; and
22) —NR 13 —S(O) 2 NR 13 R 14 ;
n is 0, 1, 2, 3, or 4; r is 1, 2, 3, or 4, and R 1 , R 3 , R 4 , and R 21 , are as defined in claim 1 .
8 . The compound of claim 1 , represented by one of Formulae (XVIII-1) (XVIII-4),
wherein each R 9 is independently selected from:
1) Halogen;
2) —CN;
3) —OR 13 ;
4) —SR 13 ;
5) —NR 13 R 14 ;
6) —OC(O)NR 13 R 14 ;
7) Optionally substituted —C 1 -C 6 alkyl;
8) Optionally substituted —C 3 -C 8 cycloalkyl;
9) Optionally substituted 3- to 8-membered heterocycloalkyl;
10) Optionally substituted aryl;
11) Optionally substituted heteroaryl;
12) —OC(O)R 25 ;
13) —C(O)NR 13 R 14 ;
14) —S(O)R 25 ;
15) —S(O) 2 —R 25 ;
16) —S(O)(NH)R 25 ;
17) —S(O) 2 —NR 13 R 14 ;
18) —NR 13 (C═O)R 25 ;
19) —NR 13 (C═O)OR 25 ;
20) —NR 13 (C═O)NR 13 R 14 ;
21) —NR 13 —S(O) 2 R 25 ; and
22) —NR 13 —S(O) 2 NR 13 R 14 ;
n is 0, 1, 2, 3, or 4; and R 1 , R 3 , R 13 , R 14 , R 21 , R 22 , R 23 , R 24 and R 25 are as defined in claim 1 .
9 . The compound of claim 1 , selected from the compounds set forth below or a pharmaceutically acceptable salt thereof:
Compound
Structure
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
10 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.
11 . A method of treating or preventing a virus infection, wherein the virus is an RNA-based virus, a coronavirus, a rhinovirus or a norovirus, in a subject susceptible to or suffering from the virus infection, the method comprising administering to the subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
12 . A method of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
13 . The method according to claim 12 , wherein the coronavirus is a 229E, NL63, OC43, HKU1, SARS-CoV or MERS coronavirus.
14 . A method of treating or preventing a virus infection in a subject susceptible to or suffering from the virus infection comprising administering to the subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
15 . A method of inhibiting viral 3C protease or viral 3CL protease in a subject, comprising administering to said subject an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
16 . A method of treating a respiratory disorder selected from the group consisting of acute asthma, lung disease secondary to environmental exposures, acute lung infection, and chronic lung infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
17 . The method according to claim 12 , wherein the compound or pharmaceutically acceptable salt thereof is administered orally, subcutaneously, intravenously or by inhalation.
18 . The method according to claim 12 , wherein the subject is a human.
19 . The method of claim 12 , wherein the coronavirus is SARS-CoV-2.
20 . The compound of claim 9 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
21 . The compound of claim 9 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
22 . The compound of claim 9 , wherein the compound is
or a pharmaceutically acceptable salt thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.